Comparator Sourcing: How to De-Risk Your Comparative Drug Supply Strategy

Roughly two-thirds of clinical trials rely on a comparator or co-therapy — and sourcing it is one of the most underestimated parts of the whole supply chain. In one industry survey, around three-quarters of respondents said they'd hit a challenge sourcing comparators or ancillaries. And the money is far from trivial: by some long-standing estimates, sponsors spend on the order of $50 million on clinical supplies for a program, with roughly half of that going to comparators.

Yet comparator sourcing is often treated as an afterthought — something to handle once the protocol is locked. By then the market may have moved against you, your options have narrowed, and the price has climbed. This guide walks through why comparator sourcing is so difficult and, more importantly, how to build a comparative drug supply strategy that de-risks the trial instead of threatening it.

What is a comparator drug, and why is sourcing it so hard?

A comparator is an existing, usually already-approved drug used as the benchmark against which your investigational product is measured — alongside co-therapies and other non-investigational medicines a protocol may require. Unlike your own IMP, you don't manufacture it; you have to buy it on the open market or source it directly, in the right quantities, at the right time, with full documentation, often across multiple countries.

That's where the difficulty comes from. You're buying a commercial product that wasn't made for your trial, in a market you don't control, under regulatory and quality constraints that are stricter than ordinary procurement.

The core challenges of comparator sourcing

Knowing where the risk concentrates is the first step to managing it. These are the recurring pressure points.

• Scarcity and demand. High-demand comparators — particularly in oncology and other competitive therapeutic areas — can be genuinely hard to obtain in trial quantities, and you may be competing with other sponsors for the same product.
• Rising and volatile pricing. Comparator costs have escalated, and because supply teams build in overage to cover uncertainty, every price increase is multiplied by the buffer you're carrying. Expensive comparators make overage expensive.
• Short shelf life and expiry. A comparator with limited remaining shelf life forces more frequent resupply campaigns and drives waste through expiry replacement — a major, often hidden cost.
• Lead times. Manufacturer lead times, production schedules, and batch sizes all have to be understood up front. Underestimate them and you're exposed to delays you can't recover from mid-trial.
• Regulatory and cross-border rules. Requirements vary by country — including whether a comparator sourced in one region can legally be used in a trial in another — layered on top of general import/export and trade regulations.
• Pedigree, traceability, and counterfeit risk. Without proper documentation and chain-of-custody, you risk introducing product you can't fully verify, which is both a quality and a regulatory exposure.
• Data disclosure. Sourcing directly can reveal information about your trial earlier than you'd like. The route you choose has confidentiality implications.

Direct vs. open-market sourcing: choosing the right route

One of the most consequential decisions in your strategy is how you source. The two main routes have different trade-offs.

Direct sourcing (from the manufacturer) gives you a controlled, traceable supply with clear pedigree — but it can mean longer lead times, larger minimum quantities, higher prices in some cases, and earlier disclosure of your trial's existence to the manufacturer.

Open-market sourcing (through wholesalers and distributors) often brings shorter lead times and more competition — particularly in Europe, where multiple wholesalers compete and can drive prices down. It can also let you establish supply without early data disclosure. The trade-off is that you must rigorously verify pedigree, traceability, and stock continuity, because you're a step removed from the manufacturer.

Neither route is universally "right." The best strategy frequently blends them — and choosing well requires understanding each provider's re-supply timescales, stock volumes, and the remaining shelf life of what they're holding.

How to de-risk your comparator supply strategy

Here's the practical approach we take with sponsors to turn comparator sourcing from a liability into a managed process.

1. Start early — before the protocol is locked. The single biggest mistake is treating sourcing as a post-protocol task. Engage sourcing while the design is still flexible, so trial parameters and supply reality can inform each other.
2. Let supply and clinical talk to each other. Protocol choices — visit intervals, titration schedules, drop-out assumptions — directly drive comparator waste. Small design adjustments (for example, a longer visit interval) can dramatically cut the quantity you need to source.
3. Right-size overage with risk-based modeling. Because comparators are expensive, blanket overage is costly. Model the actual risk and source to cover that, rather than padding heavily by rule of thumb.
4. Align sourcing frequency with shelf life. Source in campaigns that overlap intelligently with remaining shelf life. Sourcing too infrequently against a short shelf life creates sharp, wasteful expiry-replacement events with no slack for delays.
5. Build traceability in from the first purchase. Insist on full pedigree and documentation regardless of route — it's your protection against counterfeit risk and your evidence in an inspection.
6. Map the regulatory route per country. Confirm, country by country, whether your chosen comparator source is acceptable for each trial site, and plan import/export accordingly.
7. Plan contingencies. Build buffer time into the schedule and identify alternative sources before you need them. The time to find a backup is not the day your primary supply falls through.

Why experience matters here

Comparator sourcing rewards experience more than almost any other part of clinical supply, because so much of it is judgment: reading the market, knowing which wholesalers are reliable in which regions, anticipating which comparators are about to get tight, and knowing when a slightly more expensive source with shorter lead times is actually the cheaper choice once you account for shelf life and waste. That kind of know-how is hard to build from scratch mid-trial — which is exactly why many sponsors bring in a partner who already has it.